daemon@ig.UUCP (12/07/87)
From: CZJ%NIHCU.BITNET@CUNYVM.CUNY.EDU
Attached is the Table of Contents and interesting items from the
December 4 NIH Guide to Grants and Contracts.
Jim Cassatt (czj@nihcu.bitnet)
--------------------------------------------------------------------
Vol. 16, No. 39, December 4, 1987
DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE)
OPERATION OF A PNEUMOCOCCAL POLYSACCHARIDE
SEROLOGICAL REFERENCE LABORATORY (RFP)..(84/122)..........................1
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES
SPECIALIZED CENTERS OF RESEARCH IN CARDIOPULMONARY
DISORDERS DURING SLEEP (RFA)...(125/175, 1204/1692).......................1
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD
PATHOBIOLOGY OF BONE MARROW SUPPRESSION IN AIDS OR
AIDS-RELATED COMPLEX (RFA)..(178/238, 1696/2109)..........................2
National Heart, Lung, and Blood Institute
National Institute of Diabetes and Digestive and Kidney Diseases
Index: HEART, LUNG, AND BLOOD
DIABETES AND DIGESTIVE AND KIDNEY DISEASES
MOLECULAR BIOLOGY DATA - REPRESENTATION/ANALYSIS BY COMPUTER (RFA).(241/437).3
National Library of Medicine
Index: NATIONAL LIBRARY OF MEDICINE
STUDIES FOR DEVELOPING PROCEDURES TO EVALUATE THE SAFETY OF
BOUND DRUG RESIDUES (RFA)...(440/497).....................................5
Food and Drug Administration
Index: FOOD AND DRUG ADMINISTRATION
ONGOING PROGRAM ANNOUNCEMENTS
HYPERTENSION, DIABETES AND THE VASCULATURE (PA)...(504/650)..................6
National Heart, Lung, and Blood Institute
National Institute of Diabetes and Digestive and Kidney Diseases
Index: HEART, LUNG, AND BLOOD
DIABETES AND DIGESTIVE AND KIDNEY DISEASES
MINORITY INVESTIGATOR RESEARCH SUPPLEMENT (PA).(653/828).....................8
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD
BIOCHEMISTRY OF ANTIVIRAL AGENTS IN EUKARYOTIC CELLS (PA)..(831/927).........10
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES
EXPRESSION OF THE HUMAN OKT4 ANTIGEN ON THE SURFACE OF
NON-LYMPHOID CELLS (PA)..(930/1035).......................................11
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES
CHILD AND ADOLESCENT MENTAL HEALTH ACADEMIC AWARD (PA)..(1041/1076)..........13
National Institute of Mental Health
Index: MENTAL HEALTH
K AWARDS
GERIATRIC MENTAL HEALTH ACADEMIC AWARD (PA)....(1079/1107)...................14
National Institute of Mental Health
Index: MENTAL HEALTH
K AWARDS
ERRATUM
RESEARCH CENTERS FOR AIDS DEMENTIA AND OTHER
RETROVIRUS-ASSOCIATED NEUROLOGICAL DISORDERS..(1124/1133).................14
National Institute of Neurological and Communicative Disorders and Stroke
Index: NEUROLOGICAL AND COMMUNICATIVE DISORDERS AND STROKE
-------------------------------------------------------------------
MOLECULAR BIOLOGY DATA - REPRESENTATION/ANALYSIS BY COMPUTER
RFA AVAILABLE: 88-LM-01
P.T. 34; K.W. 1002008, 1004008, 0790000
National Library of Medicine
Application Receipt Date: February 12, 1988
The National Library of Medicine invites grant applications from investigators
who are interested in the computer and information science aspects of
molecular biology data management and analysis. The objective is to promote
high quality research that has value for furthering our understanding of
structure/function relationships in nucleic acids, proteins, and other
biologically important molecules, in order to help prevent, diagnose, and
treat human disorders. This NLM Request for Application does not supersede
the relevant, ongoing program interests of other NIH components as indicated
by a similar invitation in May 1987 (Program Announcement - NIH Guide, Vol.
16, No. 18.). However, it is possible that special NLM funds will be available
in FY 1988 to support competitive research programs that further the stated
goals. Potential applicants are strongly advised to contact NLM staff before
submitting applications for support.
BACKGROUND
The appearance of new experimental methods in the past several years has
greatly increased the rate at which data are accumulating about the molecular
control of life processes. Restriction enzymes, synthetic molecular probes,
efficient microchemical methods for DNA and protein sequence determination,
and recombinant DNA technology have developed to the point that it is now
feasible to consider large-scale projects, such as the systematic analysis of
entire eukaryote genomes. Because of their size and complexity, the data that
are generated by such undertakings must be analyzed and compared using
computerized techniques for storage, searching, and analysis. The computer
databases that hold this information, currently numbered in millions of
nucleotide base pairs and thousands of amino acids, are expected to grow by
three orders of magnitude to encompass sequences totalling billions of
nucleotides. Current methods for structuring, searching, and analyzing such
databases need to be enhanced correspondingly.
RESEARCH GOALS
Research projects which foster the development of new computer-based analysis
methods for the interpretation of molecular biological data are invited. Such
research will require a diversity of approaches and make use of data from a
number of model systems. The research topics of interest described below are
intended to illustrate the range of work in computer and information science,
as applied to biology, that will be needed to advance our research
capabilities in the area of genomic analysis and macromolecular structure and
function.
o Methods and algorithms for improving the efficiency of information
retrieval through operations that are computationally intensive
(e.g., cannot be performed in linear time).
o Expert system techniques for automatic generation of annotation
information concerning sequence data, creation of linkages among
related databases via explicit pointers or common vocabulary.
o Software algorithms and other database query methods capable of
translating natural language questions into appropriate retrievals
from multiple related factual databases.
o Database design, incorporating data representations that are
optimal for search, analysis, transmission, and storage of
macromolecular data.
o Algorithms capable of predicting structure and/or function based on
primary sequences of nucleotides and amino acids.
o Methods of pattern recognition based on associative networks and
algorithms design optimized for multiprocessor (e.g., parallel
processor) machine architectures.
3
MECHANISM OF SUPPORT
Support for this program will be through research project grants (R01).
Policies that govern research grant programs of the National Institutes of
Health apply to this program. Since it is anticipated that potential
applicants may wish to enlarge on currently available databases, consortium
arrangements are also possible. In addition, collaborative projects between
persons with engineering, analytical, and information science skills and
molecular biologists are encouraged.
The total amount available for support of grants under this RFA is contingent
upon the appropriation of funds for this purpose. The number of awards will
be determined by the merit of the proposals and by their relevance to the
program goals, as well as by the availability of funds. It is anticipated
that in fiscal year 1988 up to one million dollars will be allocated to the
research initiatives described in this RFA. This amount may be increased if a
large number of highly meritorious applications are received and if funds are
available.
APPLICATION AND REVIEW PROCEDURES
Prior to initial scientific merit review, a triage mechanism may be employed
to screen out applications that are clearly noncompetitive or nonresponsive to
the RFA. Such applications would be returned to the applicant. Applications
will be evaluated initially by a special NLM peer review committee for
scientific and technical merit. A second review will be conducted by the
Board of Regents of the National Library of Medicine. Review criteria include
the following:
o Overall scientific merit of the research;
o Potential value of the research for furthering the understanding
and utilization of genomic and other macromolecular information;
o Feasibility of the research and adequacy of the experimental
design;
o Training, experience, research competence, and dedication of the
investigator(s);
o Adequacy of available facilities; and
o Appropriateness of the requested budget for the work proposed.
METHOD OF APPLYING
Applications should be submitted on the new form PHS 398 (rev. 9/86). The
RFA label, available in the revised application kit, MUST be affixed to the
bottom of the face page. Failure to use this label could result in delayed
processing of the application such that it may not reach the review committee
in time. Application kits are available at most institutional business or
grants offices and from:
Office of Grants Inquiries
Division of Research Grants
Westwood Building, Room 449
National Institutes of Health
Bethesda, Maryland, 20892
Applications will be accepted in accordance with the following schedule:
TIMETABLE
Receipt Date: February 12, 1988
IRG Review: April 1988
Board Review: May 17-18, 1988
Earliest Funding Date: July 1, 1988
It is essential that applicants type "Molecular Biology Data -
Representation/Analysis by Computer" and the RFA Number 88-LM-01 on line 2 on
the face page of the application form. The original and four copies of the
application should be submitted to the following office:
4
Grant Application Receipt Office
Division of Research Grants
Westwood Building, Room 240
National Institutes of Health
Bethesda, MD 20892
To expedite the review process, submit two copies of your application directly
to:
Biomedical Information Support Branch
Extramural Programs
National Library of Medicine
Lister Hill Building, Room 5S-522
Bethesda, MD 20894
Funding decisions will be based on recommendations of the initial review group
and the Board of Regents of the National Library of Medicine regarding
scientific merit and program relevance and on the availability of funds.
It is strongly recommended, but not required, that potential applicants
contact NLM staff to discuss research objectives. Each prospective applicant
is strongly advised to submit, by January 4, 1988, a letter of intent which
includes a descriptive title of the proposed research and names of key members
of the project. This letter is requested to provide NLM staff with an
indication of the number and scope of applications to be reviewed. It does
not commit the prospective applicant to submit an application nor is it a
requirement for submission of an application. For more information,
applicants may contact:
Dr. Roger W. Dahlen
Chief, Biomedical Information
Support Branch
Extramural Programs
National Library of Medicine
Lister Hill Building, Room 5S-522
Bethesda, MD 20894
Telephone: (301) 496-4221
--------------------------------------------------------------------
MINORITY INVESTIGATOR RESEARCH SUPPLEMENT
P.T. 34, FF; K.W. 0705015, 0705065, 0750010, 0710030
National Heart, Lung, and Blood Institute
INTRODUCTION
The purpose of this announcement is to attract minority investigators to
careers in heart, lung, or blood research by providing supplemental funds to
ongoing research grants supported by the NHLBI.
DESCRIPTION
The National Heart, Lung, and Blood Institute (NHLBI) will provide support for
members of minority groups underrepresented in biomedical or behavioral
research through the Minority Investigator Research Supplement program. This
supplement addresses the recruitment of eligible individuals from the full
spectrum of minority groups, but with a special emphasis on Blacks, Hispanics,
and Native Americans.
Principal investigators who are supported by NHLBI research grants (including
RO1s, R18s, R37s, PO1s, P50s, and P60s) and who are interested in including
underrepresented minority investigators in ongoing research may submit a
request for an administrative supplement for this purpose.
ELIGIBILITY
Any principal investigator with an active R01, R18, R37, P01, P50, or P60
NHLBI grant that has a minimum of two years of research support remaining at
the time of a supplemental award is eligible to submit a request for an
administrative supplement for the purpose of recruiting a minority
investigator to work on the research grant.
A. Minority Investigator - A minority investigator is defined as an
individual from a minority group underrepresented in biomedical or
behavioral sciences. The minority investigator may be affiliated
with the applicant institution or with another nearby institution.
The program is intended for the M.D. or Ph.D. who is generally at
the junior faculty level, instructor or assistant professor, with
at least one year postdoctoral research experience, but who has not
received previous funding from NIH as an independent investigator.
The minority investigator must make at least a two year commitment
and must spend at least 30% time on research supported by the
parent grant. This supplement is not intended to support
summer-only research.
B. Research Experience - The proposed research experience must be part
of the ongoing research of the parent grant. When an award is
issued, there should be at least two years of research support
remaining on the parent grant. As part of this research experience
the minority investigator should have the opportunity to interact
with investigators on the parent grant, should be able to
contribute intellectually to the research, and should have the
opportunity to enhance his/her research skills.
PROVISIONS
In order to receive a Minority Investigator Research Supplement there must be,
at the time of the supplemental award, a minimum of two years future support
remaining on the parent grant. In the first budget period, funds will be
provided as an administrative supplement to the ongoing research grant. In
future budget periods, funds for the minority supplement will be included in
the award to the parent grant. Each annual supplemental budget should not
exceed $30,000 in direct costs, limited to salary, supplies, and travel, and
8
may not include equipment. The continuation of support for the minority
supplement in subsequent years of the grant will depend upon a satisfactory
review of progress made, research proposed for the next budget period, and the
budget. The minority supplement progress report will be submitted as part of
the noncompeting continuation application of the principal investigator.
Funding for the supplement always is contingent on funding of the parent
grant, and cannot extend beyond the project period of the parent grant.
Supplemental awards under this program are for the sole purpose of supporting
the research experience of the minority investigator. A minority investigator
may receive support under this program on only one grant. The support should
be for a minimum of two years duration, and each parent grant can have only
one minority investigator at a time. Simultaneous or overlapping Minority
Investigator Research Supplements will not be considered.
The funding of this administrative supplement does not preclude the subsequent
submission of applications for career development awards (K series) or
investigator-initiated research grants by the minority investigator. A
minority investigator who previously received a K series award, or an
investigator-initiated research project grant from NIH is not eligible to
apply for this award.
REVIEW CRITERIA
The research training committees composed of staff from the heart, lung, and
blood programs will review requests for supplemental support under this
announcement using the following criteria:
o Prior research training and experience of the minority
investigator,
o Plans for the proposed research experience in the supplemental
request and its relationship to the parent grant, and
o Assurance from the principal investigator that the experience will
enhance the research potential and skills of the minority
investigator.
APPLICATION PROCEDURES
The principal investigator of the parent grant should submit a request for
supplemental funds directly to the NHLBI program division that supports the
parent grant. The request should include the following: 1) a letter with the
title and grant number of the parent grant and a statement that this is a
request for a Minority Investigator Research Supplement, 2) a brief 3-4 page
description of the proposed research experience and how it will expand the
capabilities and foster the independent research career of the minority
investigator, 3) a statement from the minority investigator outlining research
objectives and career goals, 4) a biographical sketch of the minority
investigator that includes a list of publications and other evidence of
scientific achievement, and 5) a proposed budget for the research experience.
The request must be signed by principal investigator and the appropriate
institutional business official.
Requests may be submitted at any time.
The original and four (4) copies of the request should be sent to the NHLBI
program division that supports the parent grant. Division representatives
are:
Dr. George A. Hayden
Research Training and Development Branch
Division of Heart and Vascular Diseases
National Heart, Lung, and Blood Institute
Federal Building, Room 3C01
National Institutes of Health
Bethesda, Maryland 20892
Telephone: (301) 496-1724
or
Ms. Diane L. Aiken
Prevention, Education, and Research Training Branch
Division of Lung Diseases
National Heart, Lung, and Blood Institute
Westwood Building, Room 640
National Institutes of Health
Bethesda, Maryland 20892
Telephone: (301) 496-7668
9
or
Dr. Christine Parker
Program Planning and Prevention Branch
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
Federal Building, Room 5C04
National Institutes of Health
Bethesda, Maryland 20892
Telephone: (301) 496-4186
or
Dr. Katrina W. Johnson
Prevention and Demonstration Research Branch
Division of Epidemiology and Clinical Applications
National Heart, Lung, and Blood Institute
Federal Building, Room 5C10B
Telephone: (301) 496-3503
The programs of the National Heart, Lung, and Blood Institute are identified
in Catalog of Federal Domestic Assistance, number 13.837, 13.838, and 13.839.
Awards will be made under the authority of the Public Health Service Act,
Section 301 (42 USC 241) and administered under PHS grant policies and Federal
regulations, most specifically 42 CFR Part 52 and 45 CFR Part 74. This
program is not subject to intergovernmental review requirements of Executive
Order 12372 or Health Systems Agency review.
---------------------------------------------------------------------
BIOCHEMISTRY OF ANTIVIRAL AGENTS IN EUKARYOTIC CELLS
P.T. 34; K.W. 1002045, 0740020, 1003002, 0760075
National Institute of Allergy and Infectious Diseases
BACKGROUND INFORMATION
The National Institute of Allergy and Infectious Diseases (NIAID) currently
supports a large number of clinical and basic research projects on the Human
Immunodeficiency Virus (HIV), the causative agent of Acquired Immunodeficiency
Syndrome (AIDS). These include research directed toward the epidemiology,
prevention, pathogenesis and treatment of the disease and its sequelae. NIAID
has undertaken a lead role in organizing scientists into the National
Cooperative Drug Discovery Groups for the Treatment of AIDS (NCDDG/AIDS). The
NCDDG/AIDS are composed of scientists from a combination of academic,
non-profit, and commercial organizations, that interact as a unit with NIAID
support, to carry out preclinical research aimed at the discovery of agents
which can be used in the treatment of AIDS. Although this program has been
favorably received, the NIAID wishes to expand the areas of
investigator-initiated research currently being funded. This Program
Announcement solicits applications from investigators who wish to play a very
active role in defining the direction of this research. While no funds are
specifically set aside for funding grants submitted in response to this
Program Announcement, additional high quality research in this area is of high
priority to the NIAID.
OBJECTIVES AND SCOPE
The objective of this Program Announcement is to stimulate research on the
biochemistry of antiviral agents in eukaryotic cells, particularly cells
susceptible to HIV infection. Directions may include elucidation of the
metabolic steps involved in activation and inactivation of nucleoside
analogues in various HIV-susceptible cells. For example, work on pyrimidine
biosynthesis in macrophages has revealed that macrophages have very low levels
of deoxythymidine kinase. This would imply that pyrimidine nucleoside
analogues may be less active in macrophages than in lymphocytes.
Investigators are encouraged but not required to form collaborations with
virologists involved in HIV biology so that uninfected and infected cells can
be compared. For example, little information is available on the effect of
HIV infection on the permeability of infected cells to nucleoside, nucleotide,
or oligonucleotide therapeutics. Other approaches may be directed toward
elucidation of unique biochemical properties of HIV-infected cells that
suggest new anti-HIV therapies. For example, characterization of viral
sequence-specific DNA-binding protein(s) may lead to development of an
oligonucleotide therapeutic to block HIV replication. Although human cells
are of primary interest, comparison of human and animal cells would fall under
the scope of this announcement. For example, comparison of human and
10
chimpanzee proteins regulated by HIV infection may shed light on the mechanism
by which replication of HIV is blocked in chimpanzees, even though their cells
carry the OKT4 receptor.
The approaches outlined above are not intended to be comprehensive or
required. Any investigations on a biochemical pathway or biomolecule present
in cells susceptible to HIV that is altered by HIV infection or that is
involved in the metabolism or mechanism of action of a potential AIDS
therapeutic are encouraged under this Program Announcement.
METHOD OF APPLICATION
Use the standard research Grant Application Form PHS 398 (Rev. 9/86). For
purposes of identification and processing, the words "NIAID Biochemistry of
Antiviral Agents in Eukaryotic Cells" should be typed in item 2 on the face
page of the application. The receipt dates will be the usual receipt dates of
Feb. 1, June 1 and Oct. 1 (as shown on pg 11 of the PHS 398 application
instructions). Mail the complete application and six (6) exact copies to:
Office of Grant Inquiries
Room 240, Westwood Building
Division of Research Grants
National Institutes of Health
Bethesda, Maryland 20892
Send a copy of the face page of the application to the individual listed below
under INQUIRIES.
REVIEW PROCEDURES AND CRITERIA
Support for this program will be through the traditional research grant.
Applications will be reviewed by the appropriate Study Sections designated by
the Division of Research Grants. A second review will be made by the National
Advisory Allergy and Infectious Diseases Council. Review criteria will be the
same as those for traditional research grant applications.
INQUIRIES
Additional information may be obtained from:
Margaret I. Johnston, Ph.D.
Head, Molecular Mechanisms Section
Developmental Therapeutics Branch
AIDS Program, NIAID
National Institutes of Health
Bethesda, Maryland 20892
Telephone: (301) 496-8197